Welcome to Xi’an Good Doctor Medical Science and Technology Co., Ltd.website !
Tel: +86 29 82681864
+86 15002902555
Internet Drug Information Service Qualification Certificate: (Shaanxi)-Non-Operating -2023-0143
Home
About
Company Profile
Enterprise culture
Intellectual Property
National Patent & Trademark
Global Patent & Trademark
Academics
Publications
Clinical Trial Sites
Clinical Application - Internal Medicine
Clinical Application - Surgery
Preclinical Studies
Products
Main Equipment
Consumable Accessories
Blog
Corporate News
Industry News
Hyperthermic Perfusion Podcast
Notice & Announcement
Investment Opportunity
Business Partnerships
After-sales Services
Become a Distributor
Contact
Contact Us
Job Opportunities
Expert Advisory Services
中
——
2025.04.21
Good Doctor. Hyperthermic Perfusion | Original: How many types of perfusion media are there in intracavitary hyperthermic perfusion treatment? How should we choose?
2025.04.16
Good Doctor·Hot Infusion | Successfully held the first 2025 annual application training class for hot infusion therapy machines
2025.04.11
Repost: Patient First | High Quality and Safety: Peking University's Famous Doctors in Taiyuan Successfully Complete Two High-Difficulty Laparoscopic Innovative Surgeries and the First Tumor Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on the Same Day in the Department of Gastrointestinal Surgery
2025.02.07
Good Doctor·Hot Infusion丨Start at the beginning, training empowers a new journey
On the first day of work, employees of Good Doctor Medical Technology Co., Ltd. quickly immersed themselves in orderly work with full enthusiasm and high spirits. All staff participated in exciting and practical training, aiming to continuously improve employees' professional skills and work efficiency, laying a solid foundation for the new year's work.
2025.01.11
Good Doctor·Hot Infusion | Focus on Growth · Co-starting a New Journey -- 2024 Xi'an Good Doctor Medical · Mid-level and Key Staff Work Report Conference
Xi’an Good Doctor Medical Science and Technology Co., Ltd. held a year-end mid-level and key staff reporting conference that carried a review and outlook. On January 9, 2025, mid-level and key staff from various departments of the company gathered together, bringing with them the hard work and fruitful results of the past year, submitting a satisfactory "answer sheet." At the same time, everyone united in strength to look forward to the future. In 2025, all departments of the company will continue to work together to embark on a new journey, empowering the new year.
2025.01.06
【Medical News】A new treatment modality for oncology—intracavitary hyperthermic chemotherapy—has been officially launched.
Recently, our hospital's oncology department successfully introduced a new green treatment model for malignant abdominal tumors - hyperthermic intraperitoneal chemotherapy (HIPEC) - and conducted the first HIPEC treatment for a patient with advanced gastric cancer.
2024.11.04
Good Doctor·Thermal Infusion丨"GD" EU Trademark Registration Successful
After the successful registration of the "GD Good Doctor" EU trademark, Good Doctor has once again obtained the "GD" EU trademark registration certificate. As a domestic hot infusion manufacturer, Good Doctor has successfully registered multiple trademarks in the EU. In the future, Good Doctor will continuously enhance its brand awareness and influence in the European market, establish a professional and reliable brand image, attract more customers and partners' attention, and strengthen the global brand competitiveness of "Made in China".
2024.09.26
Good Doctor·Hot Infusion丨Made a stunning appearance at the 2024 CSCO Academic Annual Meeting
From September 26th to 28th, 2024, the 27th National Congress of Clinical Oncology and the 2024 CSCO Annual Meeting, themed "Patient-centric, Sharing the Future", was grandly held. Jointly organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Hisk Clinical Oncology Research Foundation, this event served as a beacon, illuminating the path forward in the field of cancer treatment.